ANIX Anixa Biosciences Inc.

3.18
+0.2  (+7%)
Previous Close 2.98
Open 3.01
52 Week Low 1.33
52 Week High 5.45
Market Cap $73,063,521
Shares 22,975,950
Float 20,327,544
Enterprise Value $63,041,846
Volume 310,696
Av. Daily Volume 425,904
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Breast cancer vaccine
Phase 1
Phase 1

Latest News

  1. SAN JOSE, Calif., July 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations.  As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.  

    Going forward, Anixa's operations will center entirely on the development and expansion of its therapeutics and vaccine portfolio, which includes a cancer immunotherapy program being developed in partnership with the Moffitt Cancer Center, that uses chimeric endocrine receptor T-cell (CER-T) technology, a novel type of CAR-T.  Anixa is also developing a cancer vaccine technology addressing breast cancer with a specific focus on triple negative breast cancer (TNBC), the most lethal form of the disease, in partnership with the Cleveland Clinic.  Anixa will continue drug discovery and development of Covid-19 therapies, in partnership with OntoChem, GmbH.  In addition, Anixa will continue to examine emerging therapeutic technologies for further development.

    "Due to the evolving dynamics of the diagnostics market during this pandemic and projected disruptions in this industry, we see greater opportunity to benefit patients and our shareholders as a therapeutics-directed company," said Amit Kumar, Ph.D., Chief Executive Officer of Anixa.  "The pandemic and market forces have made it clear that we need to pivot.  Our confidence in the Cchek™ technology remains undiminished, but we feel the prudent decision is to suspend work on diagnostics at this time."

    Dr. Kumar continued, "Anixa is a company built on the efficient use of capital.  Capital allocation decisions are made based on the potential to provide the highest return to shareholders.  We are all aware of the challenges to various industries caused by the coronavirus pandemic.  The diagnostics industry is not immune, and considering this, as well as certain characteristics of our program, we have chosen this course of action.  This decision will free up capital that we can devote to advance our existing therapeutic programs and to in-license and initiate innovative new assets that will help drive the greatest value for our shareholders."

    About Anixa Biosciences, Inc.

    Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company's vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC).  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

    Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

    Anixa contact:

    Mike Catelani

     

    408-708-9808

    Tiberend Strategic Advisors, Inc. 

    Miriam Miller (Investors)

     

    212-375-2694

    Johanna Bennett (Media)

     

    212-375-2686

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-announces-strategic-program-realignment-focused-on-advancement-of-its-therapeutic-and-vaccine-pipeline-301087778.html

    SOURCE Anixa Biosciences, Inc.

    View Full Article Hide Full Article
  2. SAN JOSE, Calif., June 1, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing.  Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.

    The initial phase of this program was designed to screen approximately 1.2 billion chemical compounds, utilizing in silico methods, against two specific enzymes of SARS-CoV-2.  As the computer-based screening identified potential compounds, they would be synthesized and tested in biological assays to evaluate their potency as predicted by the molecular modeling algorithms.  Should the biological activity be verified, the compounds will be tested in animal studies to further evaluate their candidacy as Covid-19 therapeutics.  Assuming animal studies are successful, the compound or compounds can be readied for human testing. 

    Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "When we announced our strategic collaboration with OntoChem, we committed to providing frequent updates regarding the progress of our research, because Covid-19 is such an acute public health and economic problem.  Therefore, we are pleased to announce that since identifying a lead molecule, we have further identified three similar analog compounds.  These molecules target a viral protein, an endoribonuclease, that helps the virus process its genetic material during viral replication.  Before the endoribonuclease can function properly, it needs to interact with a human protein in the infected human cell.  Our in silico molecular modeling indicates that any of these four molecules might disrupt the ability of the viral endoribonuclease to interact with the human protein.  If this is confirmed in our biological testing, we believe the molecules should inhibit the viral replication process and retard the infection."

    Dr. Lutz Weber, President and CEO of OntoChem, stated, "While we continue to screen the full libraries of compounds, we are pleased that our efforts have rapidly identified four compounds.  These compounds have been synthesized and we are now engaged in testing these compounds in biological assays to verify the efficacy that was predicted in silico."

    Dr. Kumar continued, "We hope to provide an update regarding the biological testing as soon as we have completed the tests.  One of the tests is a viral replication test that utilizes active SARS-CoV-2 virus.  This test must be performed in a Biological Safety Level 3 laboratory to maintain safety and confinement."  Dr. Kumar continued, "While we are making incredibly rapid progress in our discovery efforts and hope to continue the pace of research, it's important to note that we are in the early stages of the program."

    About Anixa Biosciences, Inc.
    Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

    Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 

    Anixa contact:
    Mike Catelani
     
    408-708-9808

    Tiberend Strategic Advisors, Inc.

    Miriam Miller (Investors)
     
    212-375-2694

    Johanna Bennett (Media)
     
    212-375-2686

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-and-ontochem-have-synthesized-four-potential-covid-19-drugs-for-testing-in-biological-assays-301068026.html

    SOURCE Anixa Biosciences, Inc.

    View Full Article Hide Full Article
  3. SAN JOSE, Calif., May 4, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that it, with partner OntoChem GmbH, has identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing. 

    This is the first therapeutic candidate identified from the strategic partnership recently established by Anixa and OntoChem to evaluate over 1.2 billion molecules through an in silico study to identify potential therapies for patients infected by SARS-CoV-2, the virus that causes Covid-19 (https://ir.anixa.com/press-releases/detail/947/). Anixa believes that drugs targeting the molecular biology of SARS-CoV-2 will produce more powerful medicines than the drugs currently being evaluated in trials, most of which were repurposed from other diseases.

    This first compound is expected to disrupt the interaction of the virus's endoribonuclease with a host human protein that is necessary for the virus to replicate upon infection. Disrupting this protein-protein interaction is expected to dramatically reduce or eliminate the virus's ability to cause disease. The biological testing will initially determine how well this compound binds to the endoribonuclease, and then how well this translates into reducing viral replication in human host cells.

    Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, "While we continue to screen the full libraries of compounds, we have already identified a potential drug to be evaluated in biological testing against SARS-CoV-2. This is in contrast with most existing efforts which are repurposed compounds. With the urgency of the Covid-19 pandemic, we are pleased that this program is moving forward at such a rapid pace. As the study continues, we expect to identify several additional drug candidates that will be evaluated biologically, after which we will choose which compound to advance into animal testing. If all goes as planned, drug discovery activities could be completed within six months."

    "We are excited to have quickly identified our first 'hit' compound, and we anticipate this program will continue to advance rapidly," stated Dr. Lutz Weber, CEO of OntoChem. "To our knowledge, this project is screening the largest number of compounds with the broadest chemical diversity ever tried against SARS-CoV-2. Our expectation is that we will identify multiple candidate compounds through our in silico discovery effort while in parallel evaluating the most promising candidates in biological assays."

    Dr. Kumar continued, "Since SARS-CoV-2 has, in a matter of months, caused a global pandemic and induced tremendous economic disruptions, we intend to provide frequent updates on our progress."

    About Anixa Biosciences, Inc.
    Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.

    About OntoChem GmbH
    OntoChem GmbH is a German based company which is specialized in chemo- and bio-IT services. As a data-driven company, OntoChem is using AI techniques to answer project specific questions and is supporting scientists to discover knowledge in the life sciences eco-system. OntoChem is located in Halle (Saale) and Stuttgart. Having started in 2005, the team has a long history of developing and applying ontologies, software tools and data streams for life and material science customers. More on OntoChem at www.ontochem.com.

    Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 

    Anixa contact:
    Mike Catelani
     
    408-708-9808

    Tiberend Strategic Advisors, Inc.

    Miriam Miller (Investors)
     
    212-375-2694

    Johanna Bennett (Media)
     
    212-375-2686

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-and-ontochem-announce-discovery-of-first-covid-19-therapeutic-candidate-301051289.html

    SOURCE Anixa Biosciences, Inc.

    View Full Article Hide Full Article
  4. SAN JOSE, Calif., April 23, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Biomarker Insights.  The article, entitled "Detecting Prostate Cancer Using Pattern Recognition Neural Networks with Flow Cytometry-Based Immunophenotyping in At-Risk Men," supports the use of Anixa's Cchek™ early cancer detection technology as a tool to improve prostate cancer detection and reduce unnecessary biopsies.

    Cchek™ is an artificial intelligence (AI)-driven platform developed as a simple blood test to detect solid tumors by screening for the body's immune response to the presence of a malignancy.  The technology uses flow cytometry of white blood cells and AI to identify tumor-bearing patients.

    The journal article, co-authored by Anixa with collaborators from the Wistar Institute, the MD Anderson Cancer Center at Cooper and the Cooper Medical School of Rowan University and New Jersey Urology, LLC, highlights study data demonstrating Cchek's™ ability to distinguish healthy men from high-risk prostate cancer patients with a sensitivity (the ability to identify patients with the disease) of 96.6% and a specificity (the ability to correctly identify healthy subjects) of 87.5%.  In addition, Cchek™ demonstrated an ability to distinguish, among men scheduled for biopsy, those with high-risk prostate cancer from those with benign conditions or low-grade cancer, for which surgery is not required and a biopsy is unnecessary.

    Amit Kumar, Ph.D., Chief Executive of Anixa and the study's senior author, stated, "The Anixa team is excited by the publication of our scientific paper in Biomarker Insights.  Our goal with Cchek™ has been to develop an inexpensive blood test that accurately detects the presence of cancer by measuring the body's immune response.  Based on these results, Cchek™ appears able to not only accurately identify men with prostate cancer, but also distinguish, with considerable accuracy, men who are disease free."

    The Biomarker Insights article is available to view at the following link:  https://doi.org/10.1177/1177271920913320.

    The journal article's lead author is George A. Dominguez, Ph.D., Senior Clinical Research Scientist at Anixa.  The co-authors are Alexander T. Polo, John Roop, Anthony J. Campisi and Amit Kumar, Ph.D. from Anixa Biosciences; Dmitry I. Gabrilovich, MD, Ph.D from the Wistar Institute; Robert A. Somer, MD from the MD Anderson Cancer Center at Cooper and the Cooper Medical School of Rowan University; and Adam D. Perzin, MD from New Jersey Urology, LLC.

    About Cchek™
    Cchek™ is an early cancer detection technology, that measures a patient's immunological response to a malignancy by analyzing immune system cells in peripheral blood.  The goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure.  Further, conventional methods using current cancer screening tests often lack accuracy and reliability.  Anixa's orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency.  To date, Anixa has successfully used Cchek™ to detect the presence of 20 different cancers including lung, colon, breast and prostate.  The robust cancer detection performance of Cchek™ makes it a platform from which multiple cancer diagnostic tests may be developed.  The CLIA validated Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test, is the first commercial test developed with the Cchek™ liquid biopsy technology.

    About Anixa Biosciences, Inc.
    Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

    Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 

    Anixa contact:
    Mike Catelani

    408-708-9808

    Tiberend Strategic Advisors, Inc.

    Miriam Miller (Investors)

    212-375-2694

    Johanna Bennett (Media)

    212-375-2686

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-publication-of-peer-reviewed-journal-article-in-biomarker-insights-highlighting-cchek-liquid-biopsy-technology-301045830.html

    SOURCE Anixa Biosciences, Inc.

    View Full Article Hide Full Article
  5. SAN JOSE, Calif., April 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that it has entered into a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. 

    Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, "There are a number of drugs that are either in, or will shortly be in, clinical trials against COVID-19.  While we unquestionably hope one or more of those drugs is successful, we must note that all those drugs were developed for other viruses and other diseases.  During this very acute pandemic, it's expected that previously developed molecules will be tried, to quickly determine if something is effective.  However, we believe that newly designed drugs that are purposefully developed to specifically target SARS-CoV-2, enabled by the recent studies of the molecular biology of this virus, will have the potential to be far more effective than hoping to get lucky with a repurposed drug.  Therefore we are initiating this program to identify drugs that may have much greater efficacy.  Additionally, the research plan is designed to identify compounds that might have efficacy not only against SARS-CoV-2, but other similar viral diseases as well."

    While Anixa has primarily focused in oncology, its nimble and flexible capital efficient business model, enables it to effectively address new critical unmet needs such as this dynamic pandemic.  Further, Dr. Kumar has previous experience working in the infectious disease area, including work done with the SARS-virus that emerged in 2003.  In fact, Dr. Kumar and his company at that time, worked with a number of government agencies including the Department of Defense to develop technologies to detect and monitor deadly infectious diseases.  In performing that work, Dr. Kumar made presentations to various members of the U.S. Senate and House regarding upcoming and emerging diseases.  Considering the acute public health and economic problems caused by COVID-19, Anixa felt it was important to utilize its expertise and leverage its business model to address this pandemic.

    Dr. Kumar continued, "We are pleased to be working with OntoChem for the discovery and development of new drug candidates for COVID-19.  OntoChem has developed the world's largest chemistry and gene ontology databases and search capability and has assembled large, proprietary, in silico libraries of chemical compounds that could disrupt the ability of SARS-CoV-2 to replicate.  In silico refers to the existence of compounds in a computer database with detailed molecular structures.  In addition to its proprietary libraries, OntoChem has access to other libraries of potential drug compounds.  After recent publications of the RNA sequence, as well as key crystal structures of certain enzymes of the virus, we approached OntoChem to collaborate on a project to utilize their proprietary technologies for drug discovery." 

    Dr. Lutz Weber, President and CEO of OntoChem stated, "The discovery of investigational drug candidates can ordinarily take several years.  However, through this collaboration, we anticipate identifying multiple drug candidates in as little as six months' time.  To do this, we will utilize advanced computational methods, machine learning and molecular modeling techniques to perform in silico screening of over 1.2 billion compounds to evaluate if any could disrupt one of two key enzymes of the virus.  This comprehensive group of over 1.2 billion compounds includes publicly available and OntoChem's proprietary libraries.  To our knowledge, this project will utilize the largest number of compounds with the broadest chemical diversity ever tried against SARS-CoV-2.  Due to the size and diversity of the compounds, we are very optimistic about success.  After identifying key compounds, we will have them synthesized and evaluated in biological and cellular assays to assess their potency.  Following that work, we hope to have a small number of candidates that can be taken into animal studies."

    Dr. Weber continued, "This project is a very promising approach to identifying and developing a drug specifically for COVID-19.  Following publication of recent information about COVID-19, we were evaluating certain projects addressing this disease agent.  We were pleased that Anixa proposed this collaboration to work together using both companies' collective expertise and our proprietary technologies." 

    COVID-19 Program Description:
    The Anixa-OntoChem COVID-19 program will focus on two specific proteins of the coronavirus.  The first protein is the main protease, Mpro, which is an enzyme of the virus that severs a large poly-peptide into functional proteins that enable the virus to replicate in the human host.  The program will attempt to identify molecules that inhibit the function of this enzyme, and potentially stop or slow down the virus' ability to replicate and cause disease.  Since this protease does not have human analogs, potential inhibitors may not affect any human proteins and therefore toxic side effects may be minimized.  Several crystal structures of this enzyme have been published, including a high resolution image published on March 20, 2020 (Science 2020, DOI 10.1126/science.abb3405), which induced Dr. Kumar's interest in targeting this protein.  Using high performance computing and artificial intelligence, Anixa and OntoChem will identify molecules in the various libraries comprised of 1.2 billion compounds, which might inhibit this protein.  One very attractive chemical library is a proprietary, multi-component reaction library created and owned by OntoChem utilizing its extensive database of chemical reactions. 

    The second target is an endoribonuclease, which plays a role in breaking up the ribonucleic acid, or the genetic content, of the virus.  Recent studies have demonstrated that the endoribonuclease of many viruses, including the SARS virus of 2003 and it is believed the SARS-CoV-2, binds to a human host protein.  This protein-protein interaction appears to dramatically increase the infectivity of the virus.  Because this interaction between a viral protein and a human protein appears to be common to many viruses, compounds that are able to effectively disrupt this interaction could function as broad spectrum anti-virals in addition to addressing COVID-19. 

    After identifying promising molecules through in silico screening, Anixa and OntoChem will evaluate the molecules' potential side effects, as well as their drug-like characteristics.  The molecules will then be synthesized and their activity will be evaluated with certain types of assays, which may include binding assays, cellular assays, and the ability to reduce viral activity.  Upon completion of this biological testing, the lead compounds will be tested in animals to determine which compound may be appropriate for clinical evaluation.

    Conference Call Information:
    Anixa will host a conference call and live audio webcast Tuesday, April 21, 2020, at 4:15 p.m. ET.  Interested participants and investors may access the conference call by dialing:

    • (877) 876-9174
    • Conference ID:  Anixa

    An audio webcast will be accessible via the Investors section of the Anixa website at https://ir.anixa.com/events.  An archive of the webcast will remain available for 30 days after the call.

    About Anixa Biosciences, Inc.
    Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function.  The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

    About OntoChem GmbH
    OntoChem GmbH is a German based company which is specialized in chemo- and bio-IT services.  As a data-driven company, OntoChem is using AI techniques to answer project specific questions and is supporting scientists to discover knowledge in the life sciences eco-system.  OntoChem is located in Halle (Saale) and Stuttgart.  Having started in 2005, the team has a long history of developing and applying ontologies, software tools and data streams for life and material science customers.  More on OntoChem at www.ontochem.com.

    Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 

    Anixa contact:
    Mike Catelani
     
    408-708-9808

    Tiberend Strategic Advisors, Inc. 

    Miriam Miller (Investors)
     
    212-375-2694

    Johanna Bennett (Media)

    212-375-2686

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-and-ontochem-announce-collaboration-to-develop-novel-covid-19-therapeutics-301043095.html

    SOURCE Anixa Biosciences, Inc.

    View Full Article Hide Full Article
View All Anixa Biosciences Inc. News